TCRR - TCR2 Therapeutics Announces First Quarter 2019 Earnings Conference Call and Webcast
- Earnings to be released after market close on Monday, May 13, 2019
CAMBRIDGE, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (TCR2) (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that it will release results for the first quarter 2019 and provide a corporate update on Monday, May 13, 2019, after the market closes.
TCR2 will webcast its first quarter 2019 earnings conference call on Monday, May 13, 2019, beginning at 5:00 PM ET. The live audio webcast can be accessed by clicking on the Events link in the "Investors" section of www.tcr2.com. A replay of the call will also be archived on the website and will be available until the company’s next quarterly earnings call.
About TCR2 Therapeutics
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR2’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T™ cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release. The Company’s lead TRuC-T cell product candidate, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarincoma. For more information about TCR2, please visit www.tcr2.com.
Media:
Kathy Vincent
(310) 403-8951
kathy@kathyvincent.com
Investors:
Ian Somaiya
Chief Financial Officer
(617) 949-5210
ian.somaiya@tcr2.com